HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a research note published on Wednesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.
Separately, Benchmark restated a "speculative buy" rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Unicycive Therapeutics currently has an average rating of "Buy" and an average price target of $5.50.
Read Our Latest Stock Analysis on UNCY
Unicycive Therapeutics Stock Performance
UNCY stock traded down $0.01 during midday trading on Wednesday, reaching $0.53. The stock had a trading volume of 594,662 shares, compared to its average volume of 1,138,890. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.82. The stock has a market cap of $55.03 million, a PE ratio of -0.55 and a beta of 2.30. The firm has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $0.51.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of UNCY. Great Point Partners LLC acquired a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth approximately $3,491,000. Walleye Capital LLC purchased a new stake in Unicycive Therapeutics during the third quarter worth $2,040,000. Acuta Capital Partners LLC acquired a new stake in Unicycive Therapeutics during the third quarter valued at $807,000. Bleakley Financial Group LLC purchased a new position in Unicycive Therapeutics in the third quarter valued at $33,000. Finally, Virtu Financial LLC raised its position in shares of Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after acquiring an additional 62,881 shares during the period. 40.42% of the stock is currently owned by hedge funds and other institutional investors.
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Recommended Stories
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
